Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults

Phase 1 Completed 184 enrolled HIV Vaccine Trials Network South Africa AIDS Vaccine Initiative · collab

RandomizedParallel-groupDouble-blindPrevention

Summary

Sub-Saharan Africa is the region most affected by the global Human Immunodeficiency Virus (HIV) epidemic. A vaccine is the most promising preventive approach against new HIV infections. The purpose of this study is to evaluate the safety and immunogenicity of 4 experimental preventive HIV vaccine regimens in HIV-uninfected adults in South Africa.

Timeline

Start: 2011-12-19
Primary completion: 2013-10-07
Completion: 2015-12-09

Publications

Churchyard G, Mlisana K, Karuna S, Williamson AL, Williamson C, Morris L, Tomaras GD, De Rosa SC, Gilbert PB, Gu N, Yu C, Mkhize NN, Hermanus T, Allen M, Pensiero M, Barnett SW, Gray G, Bekker LG, Montefiori DC, Kublin J, Corey L. Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. PLoS One. 2016 Sep 1;11(9):e0161753. doi: 10.1371/journal.pone.0161753. eCollection 2016.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DNA-C2	Vaccine	1 ml	Intramuscular
Subject	DNA-C2	Vaccine	4 mg	Intramuscular
Subject	SAAVI MVA-C	Vaccine	0.5 ml	Intramuscular
Subject	SAAVI MVA-C	Vaccine	2.9e+09 unknown	Intramuscular
Subject	gp140	Vaccine	100 ug	Intramuscular
Subject	gp140	Vaccine	0.5 ml	Intramuscular
Background	MF59	Other / unclassified	—	Intramuscular

Indications

No indication recorded.